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Background: Brachial-ankle pulse wave velocity (baPWV) is a method to estimate arterial stiffness, which reflects the
stiffness of both the aorta and peripheral artery; it would be applicable to general practice, since its measurementis
automated. The aim of this study was to evaluate whether baPWV can be predictors of future cardiovascular events
(CVE) in diabetic patients.
Methods: We prospectively evaluated the association between baPWV or carotid intima-media thickness (carotid IMT) at
baseline and new onset of CVE in 1040 type 2 diabetic patients without CVE. The predictability of baPWV and/or carotid
IMT for identifying patients at high risk for CVE was evaluated by time-dependent receiver-operating-characteristic (ROC)
curve analysis.
Results: During a median follow-up of 7.5 years, 113 had new CVD events. The cumulative incidence rates of CVE were
significantly higher in patients with high baPWV values (≥1550 cm/s) as compared to those with low baPWV values
(<1550 cm/s) (p < 0.001, log-rank test). Similarly, the cumulative incidence rate of CVE was significantly higher in patients
with higher maximum carotid IMT (maxIMT) values (≥1.0 mm) as compared to those with lower maxIMT values
(<1.0 mm) (p < 0.001, log-rank test). Subjects with both “high PWV” and “high IMT” had a significantly higher risk of
developing CVE as compared to those with either “high PWV” or “high IMT,” as well as those with neither. A multivariate
Cox proportional hazards regression model revealed that both baPWV (HR = 1.30, [95%CI: 1.07-1.57]; p = 0.009) and
maxIMT (HR = 1.20, [95%CI: 1.01-1.41]; p = 0.033) were independent predictors for CVE, even after adjustment for the
conventional risk factors. Time-dependent ROC curve analyses revealed that the addition of maxIMT to the Framingham
risk score resulted in significant increase in AUC (from 0.60 [95%CI: 0.54-0.67] to 0.63 [95%CI: 0.60-0.82]; p = 0.01). Notably,
the addition of baPWV to the Framingham risk score and maxIMT resulted in further and significant (p = 0.02) increase in
AUC (0.72 [95%CI: 0.67-0.78]).
Conclusions: Evaluation of baPWV, in addition to carotid IMT and conventional risk factors, improved the ability to
identify the diabetic individuals with high risk for CVE.
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Because cardiovascular disease is the main cause of death
and impairment of quality of life in diabetic patients, early
identification of individuals at high risk for cardiovascular
events (CVE) and subsequent rapid interventions are im-
portant. Therefore, cardiovascular risk assessment based
on conventional risk factors, such as obesity, hypertension,
and dyslipidemia, is recommended for predicting CVE.
However, validation studies showed that this approach
had only moderate performance [1-3].
Recently, many studies have indicated that arterial
stiffness, which depends on the structural and geometric
properties of the arterial wall, plays a critical role in the
pathogenesis of atherosclerosis and CVE [4-6]. Among
several indices for quantifying the level of arterial stiffness,
carotid-femoral pulse wave velocity (cfPWV) is a test in
common use. Several studies have demonstrated that
higher cfPWV levels are associated with increased risk of
CVE and premature death [4,5,7-9], and it has therefore
been considered as the gold standard for evaluation of
central aortic stiffness. However, accurate measurement of
cfPWV levels requires specialized training and a cumber-
some procedure, and it has not been applied in routine
clinical practice.
Brachial-ankle pulse wave velocity (baPWV) is another
method to estimate arterial stiffness. It reflects the stiff-
ness of both the aorta and peripheral arteries in an arm
and a leg, and would be more applicable to general prac-
tice since its measurement, which uses a separate cuff
for each limb, is automated and easier to perform than
cfPWV [10-12]. Because baPWV was shown to be corre-
lated with cfPWV in several cross-sectional studies
[13,14], it could also be a good predictor of CVE. Indeed,
several studies have shown that baPWV is an independ-
ent predictor of the presence of coronary artery disease
[15], myocardial injury [16], and future CVE [17,18].
However, it remains unclear whether measurement of
baPWV can add prognostic information beyond conven-
tional cardiovascular risk markers in patients with type 2
diabetes.
On the other hand, many studies have revealed close
associations between carotid atherosclerosis and cardio-
vascular disease. Carotid ultrasonography is a simple and
non-invasive procedure that has allowed clinicians to
visualize the characteristics of the carotid wall and lumen
surfaces to quantify the severity of atherosclerosis. In par-
ticular, carotid intima-media thickness (IMT) is a useful
marker of the progression of atherosclerosis throughout
the body, and has been shown to be a predictor of CVE
[17,19-25]. Thus, carotid IMT is considered one of the
most appropriate screening tools for identifying high-risk
individuals.
On this background, the present study prospectively
evaluated whether measurement of baPWV can addprognostic information beyond conventional cardiovascu-
lar risk markers in patients with asymptomatic type 2 dia-
betes. Furthermore, this study also evaluated whether the
addition of baPWV values to conventional risk factors and
maximum carotid IMT (maxIMT) can improve the pre-
dictability of CVE in this population.
Methods
Subjects
The present study was based on data obtained from the
Study of Order-Made multiple Risk Factor Intervention
Trial (OMRFIT), which is an ongoing multicenter cohort
study to investigate the genetic risk factors for diabetic
complications, and has recruited more than 4000 diabetic
patients. The present study included a total of 1040 type 2
diabetic patients who were registered at either Osaka
University Hospital or Naka Memorial Clinic, where the
measurement of baPWV and ankle brachial index (ABI)
was performed routinely. Patients were enrolled during
January-December 2005 and fulfilled the following criteria
at baseline: (I) diagnosis of type 2 diabetes based on cri-
teria of the Japan Diabetes Society (early-morning fast-
ing plasma glucose (PG) ≥126 mg/dL, two-hour PG
after 75 g glucose load ≥200 mg/dL, or casual plasma
glucose ≥200 mg/dL) [26], (II) exclusion of a diagnosis
of coronary heart disease (CHD), cerebral infarction, or
peripheral artery disease (PAD) based on medical inter-
views, physical examinations, and screening examina-
tions, including electrocardiogram, chest X-ray, and
ABI, (III) measurement of baPWV. The study protocol
was approved by the committees on the ethics of hu-
man research of Osaka University Graduate School of
Medicine. Written informed consent was obtained from
all the participants after they received a full explanation
of the study.
Clinical and biochemical analyses
Clinical and biochemical data were collected at baseline.
A structured questionnaire was used to determine med-
ical history including duration of diabetes, current medi-
cation use, and smoking status. Smoking status was
evaluated as a value of 0 or 1 when Brinkman’s Index (the
number of cigarettes per day x smoking years) was less
than 200 or higher than 200, respectively. Blood pressure
was measured at rest with a mercury and/or automated
sphygmomanometer. Measurement of ABI was performed
with subjects in the supine position after at least 5 min
of rest, using a volume-plethysmographic apparatus
(BP-203RPE II form PWV/ABI; Omron Healthcare Co.,
Ltd., Kyoto, Japan). Fasting blood samples were col-
lected and hemoglobin A1c (HbA1c), serum total, LDL,
and HDL cholesterol, and serum triglyceride (TG) levels
were measured using standard laboratory protocols. The
determination of hypertension (defined as systolic blood
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(DBP) ≥80 mmHg or anti-hypertensive medication use) and
dyslipidemia (defined as serum LDL cholesterol ≥3.1 mmol/
L (120 mg/dl) or serum TG ≥1.7 mmol/L (150 mg/dl) or
HDL-cholesterol <1.0 mmol/L (40 mg/dl) or lipid-lowering
medication use) was based on the criteria of the
Japan Diabetes Society [26]. The risk of CVD was also
estimated, using the Framingham D’Agostino equations
[26], with gender, age, total cholesterol, HDL cholesterol,
systolic blood pressure, antihypertensive medication use,
current smoking status, and diabetes status included
as risk factors in the model.
Measurement of baPWV
Measurement of baPWV was performed using the same
volume-plethysmographic apparatus as for ABI (BP-203RPE
II form PWV/ABI), with subjects in the supine position after
at least 5 min of rest [10,11,13]. Four oscillometric cuffs,
each connected to a plethysmographic sensor that deter-
mined volume pulse form and to an oscillometric pressure
sensor that measured blood pressure, were wrapped on both
the brachia and ankle and two electrocardiogram electrodes
were placed on each wrist They were simultaneously
pressurized to the approximate value of the patient’s
diastolic pressure so that the pulse volume waveforms
could be recorded using semiconductor pressure sen-
sors. The distance between sampling points of baPWV
was calculated automatically according to the height of
the subject. The path length from the suprasternal
notch to the ankle (La) was calculated as: La = 0.8129*height
(in cm) + 12.328. The path length from the suprasternal
notch to the brachium (Lb) was calculated as: Lb =
0.2195*height - 2.0734. The baPWV was calculated ac-
cording to the following formula: baPWV = (La - Lb)/
Tba, where Tba was the time interval between the
wave front of the brachial waveform and that of the
ankle waveform [13]. Two simultaneous measurements
of baPWV were recorded, on the right side and left
side, respectively, and the higher of these readings was
used as the representative value for each individual.
Measurement of Carotid IMT
B-mode ultrasonography of the carotid artery was per-
formed using an ultrasound machine (SDU 2200, Shimazdu
Medical Inc., Japan) with a 7.5-MHz linear transducer. In
accordance with the guidelines of the Japan Society of
Ultrasonics [27], all scanning was conducted by experi-
enced laboratory physicians using the same ultrasound
system and the same measuring method. Scanning of
the extracranial common carotid artery, the carotid
bulb, and the internal carotid artery in the neck was
performed bilaterally from three different longitudinal
projections (i.e., anterior-oblique, lateral, and posterior-
oblique). The carotid IMT was measured as the distancefrom the leading edge of the first echogenic line to the
leading edge of the second echogenic line using computer
software (Intima-scope; Media Cross Inc., Tokyo, Japan).
The thickest points of IMT (including plaque lesions) in
the common carotid artery, the carotid bulb, and the
internal carotid artery were measured separately, and the
highest value among them was defined as maxIMT and
used as the representative value for each individual [27].
Assessment of cardiovascular events
The prespecified outcome during the follow-up period
was the first occurrence of CVE, which included any coron-
ary heart disease (CHD) event (coronary death, myocardial
infarction, angina, and coronary revascularization), any
cerebrovascular event (ischemic stroke, hemorrhagic
stroke, and transient ischemic attack), peripheral artery
disease (PAD), and heart failure. The occurrence of acute
coronary syndrome, stroke, heart failure, sudden death
and cardiac death were defined as the major CVE. Diag-
nosis of occurrence of a CHD event was performed by
cardiologists based on the clinical symptoms, characteris-
tic ECG changes, cardiac enzyme levels, and findings in
coronary angiography and/or echocardiography, according
to established guidelines [28,29]. An ischemic stroke event
was defined as a validated definite or probable hospitalized
atherothrombotic, cardioembolic, lacunar, or other type of
ischemic stroke, diagnosed by neurosurgical experts based
on clinical symptoms and neuroimaging findings, accord-
ing to the National Institute of Neurological Disorders
and Stroke (NINDS) III classification [30]. The presence
of lower extremity PAD was defined as the highest
stenosis observed on either the right or left side. An
ABI <0.9 was diagnostic of occlusive arterial disease in
patients with or without symptoms. The measurement
of ABI was performed approximately annually during
the follow-up period and subjects whose ABI value de-
creased to below 0.9 were diagnosed as developing
PAD. Diagnosis of chronic heart failure was performed
by cardiologists based on the clinical symptoms, char-
acteristic chest X-ray changes, plasma BNP levels, and
findings in other tests, including echocardiography and
cardiac catheter test, according to the Guidelines for
Treatment of Chronic Heart Failure published by the
Japanese Circulation Society [31,32].
All patients were followed up at each hospital visit, or
by telephone if necessary, and the occurrence of medical
events was determined. For potential new CVE, add-
itional information, including the results of imaging and
other diagnostic procedures, was obtained for confirm-
ation, and all causes of death were confirmed by hospital
records. For participants with incident CVE, follow-up
duration was defined as the period between the baseline
clinic visit and the date of the first CVE. For participants
with no CVE, follow-up continued until the date of
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contact. Patients were allowed to use any concurrent
treatment.
Statistical analyses
All values are reported as mean ± SD, or median for con-
tinuous variables, or number with percentage in paren-
theses for categorical variables. The occurrence of CVE
and major CVE were plotted using the Kaplan-Meier
method and differences between the groups were assessed
by a log-rank test. Univariate and multivariate Cox pro-
portional hazards regression models were used to deter-
mine the association of each variable with the outcome,
and hazard ratios (HRs) and 95% confidence interval (CI)
were reported. Statistically significant variables in the un-
adjusted analyses were entered into the multivariate model
to reveal the independent impact on the outcome.
The ability of variables to predict CVE and major CVE
were examined by time-dependent receiver-operating-
characteristic (ROC) curve analysis [33]. Curves were
generated from models of the prediction of risk using
Framingham risk score (FRS) alone, or with carotid IMT,Table 1 Baseline characteristics of the overall study populatio
maxIMT
Parameters All patients (n = 1040) baPWV
<1550 cm/s (n =
Gender (male,%) 65.0 65.4
Age (years) 58.9 ± 9.6 55.2 ± 10.1
Smoking habit 47.9 47.5
Body mass index (kg/m2) 23.9 ± 3.5 24.0 ± 3.9
HbA1c (%) 7.2 ± 1.1 6.7 ± 1.1
Duration of diabetes (years) 4.8 ± 4.4 4.2 ± 3.2
Systolic BP (mmHg) 131 ± 17 126 ± 16
Diastolic BP (mmHg) 80 ± 11 80 ± 11
Presence of hypertension (%) 73.8 63.1
Total cholesterol (mg/dl) 188 ± 29 188 ± 29
HDL cholesterol (mg/dl) 59 ± 16 59 ± 16
LDL cholesterol (mg/dl) 106 ± 24 106 ± 23
Triglyceride (mg/dl) 120 ± 89 120 ± 102
Presence of dyslipidemia (%) 70.0 69.4
Serum creatinine (mg/dl) 0.77 ± 0.36 0.75 ± 0.28
Framingham risk score (%) 27.4 ± 16.8 21.3 ± 14.3
Administration of
Anti-diabetic drugs (%) 70.3 66.3
Anti-hypertensive drugs (%) 38.8 27.7
Anti-hyperlipidemic drugs (%) 40.6 39.6
Data are shown as% or means ± SD.
*p < 0.001 for bivariate comparisons between patients classified according to the m
†p < 0.01 for bivariate comparisons between patients classified according to the me
‡p < 0.05 for bivariate comparisons between patients classified according to the meor with carotid IMT and baPWV. For all tests, p < 0.05
was considered statistically significant. The statistical




The baseline characteristics of the overall study popula-
tion and of subgroups identified according to median
baPWV level (median: 1550 cm/s) and median value of
maxIMT (1.0 mm) are shown in Table 1. Among a total of
1040 patients (males, 65.0%; age, 58.9 ± 9.6 years; diabetes
duration, 4.8 ± 4.4 years; HbA1c, 7.2 ± 1.1%), 767 (73.8%)
patients had hypertension and 728 (70.0%) had dyslip-
idemia. Mean age, HbA1c levels, duration of diabetes,
systolic blood pressure, and FRS were significantly
higher in patients with higher baPWV values (≥1550 cm/s,
n = 520) compared to those with lower baPWV values
(<1550 cm/s, n = 520) (p < 0.05). Frequencies of hyperten-
sion and antidiabetic and antihypertensive medication use
were also significantly higher in subjects with higher
baPWV (p < 0.05). There was no significant differencen and classified according to the medians of baPWV and
maxIMT
520) ≥1550 cm/s (n = 520) <1.0 mm (n = 460) ≥1.0 mm (n = 580)
64.6 62.6 66.9
62.5 ± 7.6* 55.1 ± 10.0 61.8 ± 8.2*
48.3 45.0 50.2
23.8 ± 3.1 23.8 ± 3.9 24.0 ± 3.2
6.8 ± 1.1‡ 6.8 ± 1.1 6.8 ± 1.2
5.5 ± 5.2* 4.4 ± 3.2 5.1 ± 5.1‡
137 ± 17* 128 ± 16 133 ± 17*
81 ± 11 81 ± 11 80 ± 12
84.6* 69.9 77.1†
187 ± 29 188 ± 29 187 ± 29
58 ± 17 61 ± 18 57 ± 15*
105 ± 25 104 ± 23 107 ± 24
121 ± 73 120 ± 100 121 ± 78
70.6 69.6 70.3
0.79 ± 0.43 0.74 ± 0.22 0.79 ± 0.45‡




edians of the baPWV levels and the maxIMT.
dians of the baPWV levels and the maxIMT.
dians of the baPWV levels and the maxIMT.
Katakami et al. Cardiovascular Diabetology 2014, 13:128 Page 5 of 11
http://www.cardiab.com/content/13/1/128between the two groups regarding gender, smoking habit,
BMI, diastolic blood pressure, serum total, HDL and LDL
cholesterol concentrations, triglyceride, and creatinine
levels. These findings were consistent with previous re-
ports, suggesting that high baPWV itself is closely associ-
ated with cardiovascular risk factors.
Mean age, duration of diabetes, systolic blood pressure,
serum creatinine levels, and FRS were significantly higher
and serum HDL cholesterol levels were significantly lower
in patients with higher maxIMT values (≥1.0 mm, n = 580)
compared to those with lower maxIMT values (<1.0 mm,
n = 460) (p < 0.05). Frequencies of hypertension and anti-
hypertensive medication were also significantly higher in
subjects with higher maxIMT (p < 0.05). There was no sig-
nificant difference between the two groups regarding the
other clinical parameters.
During a median follow-up of 7.5 years, 113 of the
1040 patients (10.9%) had new CVE (40 CHD events, 56
cerebrovascular events, 14 PAD, and 3 heart failure cases).
Among them, 66 cases (6 acute coronary syndrome, 56
stroke, 2 heart failure cases and 2 cardiac sudden deaths)
were defined as the major CVE. During the observation
period, 20 participants died (2 were cardiac sudden
deaths, 8 were cancer deaths, and the others were various
causes of deaths).
Univariate Cox regression analysis showed that age
(HR per 1 year = 1.08 [95%CI 1.05-1.10]; p < 0.001), dur-
ation of diabetes (HR per 1 year = 1.05 [95%CI 1.02-1.09];
p = 0.001), presence of hypertension at baseline (HR = 1.61
[95%CI 1.00-2.58]; p = 0.049), baseline systolic blood pres-
sure (HR per 1 mmHg = 1.02 [95%CI 1.01-1.03]; p = 0.004),
serum creatinine concentration (HR per 1 mg/dl = 1.54
[95%CI 1.17-2.03]; p = 0.002), and FRS (HR per 1 SD = 1.40
[95%CI 1.18-1.65]; p < 0.001) were significantly associated
with the development of CVE. Other clinical and labora-
tory variables, including gender, smoking habit, BMI,
HbA1c, diastolic blood pressure, serum LDL cholesterol,
HDL cholesterol, and triglyceride concentration, presence
of dyslipidemia, and administration of anti-diabetic,
anti-hypertensive, and anti-hyperlipidemic drugs were not
associated with the development of CVE (Additional file 1:
Table S1).
Association between baPWV and cardiovascular events
As shown in Figure 1A, the cumulative incidence rate of
CVE was significantly higher in patients with higher
baPWV values compared to those with lower baPWV
values (p < 0.001, log-rank test). Table 2 shows the results
of Cox proportional hazards regression for baPWV ana-
lyzed as a continuous variable as a predictor of CVE. A
univariate Cox proportional hazards regression model re-
vealed that the baPWV was a significant predictor of
CVE, with a 67% excess risk for each 1 SD increment (HR
per 1 SD increment = 1.67 [95%CI: 1.44-1.93]; p < 0.001).A multivariate Cox proportional hazards regression model,
in which age and gender were included as independent
variables, also revealed that the baPWV was an independ-
ent predictor of CVE (HR = 1.46 [95%CI: 1.23-1.73]; p <
0.001), even after adjustment for gender and age. Next, to
confirm that the baPWV was an independent predictor of
CVE even after adjustment for the other statistically signifi-
cant variables in the unadjusted analyses, another multi-
variate Cox proportional hazards regression model, which
included factors for gender, age, duration of diabetes,
presence of hypertension at baseline, baseline systolic
blood pressure, serum creatinine level, and FRS, was
performed. This analysis revealed that baPWV was
remained independently associated with CVE after ad-
justment for these factors (HR = 1.32 [95%CI: 1.09-1.59];
p = 0.005). Furthermore, another multivariate Cox propor-
tional hazards regression model, adjusted for conventional
risk factors and baseline therapies (gender, age, smoking
habit, BMI, HbA1c, duration of diabetes, systolic blood
pressure, HDL cholesterol, LDL cholesterol, triglyceride,
serum creatinine, administration of anti-diabetic drugs,
anti-hypertensive drugs, and anti-hyperlipidemic drugs)
also showed that baPWV was independently associated
with CVE (HR = 1.39 [95%CI: 1.10-1.61]; p = 0.004).
Analysis based on new onset of the “major CVE”
showed that the cumulative incidence rate was also
significantly higher in patients with higher baPWV
values compared to those with lower baPWV values (p =
0.001, log-rank test) (Additional file 2: Figure S1A.) Fur-
thermore, a multivariate Cox proportional hazards re-
gression model adjusted for conventional risk factors
and baseline therapies (gender, age, smoking habit,
BMI, HbA1c, duration of diabetes, systolic blood pres-
sure, HDL cholesterol, LDL cholesterol, triglyceride,
serum creatinine level, administration of anti-diabeteic
drugs, anti-hypertensive drugs, and anti-hyperlipidemic
drugs) showed that baPWV remained independently as-
sociated with the major CVE (HR = 1.32 [95%CI: 1.08-
1.78]; p = 0.011) (Additional file 1: Table S2).
Association between carotid IMT and cardiovascular events
As shown in Figure 1B, the cumulative incidence rate of
CVE was significantly higher in patients with higher
maxIMT values (≥1.0 mm) compared to those with lower
maxIMT values (<1.0 mm) (p < 0.001, log-rank test). A
univariate Cox proportional hazards regression model re-
vealed that the maxIMT was a significant predictor of
CVE, with a 46% excess risk for each 1 SD increment (HR
per 1 SD increment = 1.46 [95%CI: 1.28-1.66]; p < 0.001).
Multivariate Cox proportional hazards regression model
adjusted for conventional risk factors and/or baseline
therapies (gender, age, smoking habit, BMI, HbA1c,
duration of diabetes, systolic blood pressure, HDL chol-
esterol, LDL cholesterol, triglyceride, serum creatinine,




Figure 1 Kaplan-Meier curves depicting the cumulative probability of cardiovascular events. A The risk for cardiovascular events was significantly
greater in patients with higher baPWV values (bold line) (≥1550 cm/s, n = 520) compared to those with lower baPWV values (thin line) (<1550 cm/s,
n = 520) (p < 0.001, log-rank test). B The risk for cardiovascular events was significantly greater in patients with higher maxIMT values (bold line) (≥1.0
mm, n = 580) compared to those with lower maxIMT values (thin line) (<1.0 mm, n = 460) (p < 0.001, log-rank test). C The cumulative incidence rate of
cardiovascular events was significantly greater in the patients with “high baPWV and low maxIMT (baPWV ≥1550 cm/s and maxIMT <1.0 mm, n = 181)”
(dotted line) compared to those with “low baPWV and low maxIMT (baPWV <1550 cm/s and maxIMT <1.0 mm, n = 279)” (thin gray line) (p = 0.030,
log-rank test). The patients with “low baPWV and high maxIMT (baPWV <1550 cm/s and maxIMT ≥1.0 mm, n = 241)” (thin black line) also showed a
tendency towards a higher risk compared to those with “low baPWV and low maxIMT” (p = 0.071, log-rank test). The cumulative incidence rate of
cardiovascular events was significantly higher in the patients with “high baPWV and high maxIMT (baPWV ≥1550 cm/s and maxIMT ≥1.0 mm, n=580)”
(bold black line) compared to the other 3 groups.
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Table 2 Relative risk of cardiovascular events
HR (95% CI) p value
baPWV (per 1 SD)
Model 1 1.67 (1.44-1.93) <0.001
Model 2 1.46 (1.23-1.73) <0.001
Model 3 1.32 (1.09-1.59) 0.005
Model 4 1.35 (1.11-1.64) 0.003
Model 4 +maxIMT 1.33 (1.09-1.62) 0.004
maxIMT (per 1 SD)
Model 1 1.46 (1.28-1.66) <0.001
Model 2 1.29 (1.11-1.50) 0.001
Model 3 1.22 (1.03-1.44) 0.019
Model 4 1.22 (1.03-1.46) 0.022
Model 4 + baPWV 1.21 (1.01-1.44) 0.036
Cox proportional hazards regression analyses unadjusted (Model 1) and
adjusted for the following covariates:
Model 2, adjusted for gender and age.
Model 3, adjusted for gender and the other statistically significant variables in
the unadjusted analyses (age, duration of diabetes, presence of hypertension
at baseline, baseline systolic blood pressure, serum creatinine level, and
Framingham risk score).
Model 4, adjusted for the conventional risk factors and baseline therapies
(gender, age, smoking habit, BMI, HbA1c, duration of diabetes, systolic blood
pressure, HDL cholesterol, LDL cholesterol, triglyceride, serum creatinine level,
administration of anti-diabetic drugs, anti-hypertensive drugs, and
anti-hyperlipidemic drugs).
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drugs, and anti-hyperlipidemic drugs) also revealed that
maxIMT was independently associated with CVE (Table 2).
The cumulative incidence rate of the major CVE was
also significantly higher in patients with higher maxIMT
values compared to those with lower maxIMT values
(p = 0.003, log-rank test) (Additional file 3: Figure S1B).
A multivariate Cox proportional hazards regression
model revealed that the maxIMT was a significant pre-
dictor of the major CVE (HR per 1 SD increment = 1.30
[95%CI: 1.10-1.55]; p = 0.002), even after adjustment for
the FRS. However, another model adjusted for the con-
ventional risk factors and baseline therapies (gender,
age, smoking habit, BMI, HbA1c, duration of diabetes,
systolic blood pressure, HDL cholesterol, LDL choles-
terol, triglyceride, serum creatinine, administration of
anti-diabetic drugs, anti-hypertensive drugs, and anti-
hyperlipidemic drugs) revealed that maxIMT was no longer
a significant predictor of the major CVE (Additional file 1:
Table S2).
Next, we classified study patients into 4 groups
according to baPWV and maxIMT values: patients
with “low baPWV and low maxIMT” (n = 279), those
with “high baPWV and low maxIMT” (n = 181), those with
“low baPWV and high maxIMT” (n = 241), and those with
“high baPWV and high maxIMT” (n = 339). As shown in
Figure 1C, the cumulative incidence rate of CVE was
significantly higher in the patients with “high baPWVand low maxIMT” compared to those with “low baPWV
and low maxIMT” (p = 0.030, log-rank test). Although the
patients with “low baPWV and high maxIMT” also showed
a tendency to have a higher risk as compared to those with
“low baPWV and low maxIMT,” it did not reach statistical
significance (p = 0.071, log-rank test). Interestingly, the cu-
mulative incidence rate of CVE was significantly higher in
the patients with “high baPWV and high maxIMT”
compared to the other 3 groups. Furthermore, a multi-
variate Cox proportional hazards regression model, in
which conventional risk factors and baseline therapies
were entered, also revealed that both baPWV (HR = 1.33
[95%CI: 1.09-1.62]; p = 0.004) and maxIMT (HR = 1.21
[95%CI: 1.01-1.44]; p = 0.036) were independent predictors
for CVE (Table 2).
Similarly, subjects with both “high PWV” and “high
IMT” had a significantly (p < 0.05) higher risk of devel-
oping the major CVE as compared to those with either
“high PWV” or “high IMT,” as well as those with neither
(Additional file 4: Figure S1C.) A multivariate Cox pro-
portional hazards regression model, in which FRS, baPWV,
and maxIMT were entered, revealed that baPWV was a
predictor for the major CVE (HR = 1.61 [95%CI: 1.31-
1.97]; p < 0.001) independently of FRS and maxIMT, but
maxIMT was marginally associated with the major CVE
(HR = 1.19 [95%CI: 1.00-1.42]; p = 0.054) independently of
FRS and baPWV (Additional file 1: Table S2).
Contribution of baPWV and maxIMT in the prediction of
cardiovascular events
To examine whether the addition of baPWV and/or
maxIMT to conventional risk factors could improve the
predictability for CVE, time-dependent ROC curves
were plotted (Figure 2). The addition of maxIMT alone
to FRS resulted in a significant increase in area under
the curve (AUC) (from 0.60 [95%CI: 0.54-0.67] to 0.63
[95%CI: 0.60-0.82]; p = 0.01). Notably, the addition of
baPWV to the FRS and maxIMT resulted in a further
significant increase in AUC (from 0.63 [95%CI: 0.60-0.82]
to 0.72 [95%CI: 0.67-0.78]; p = 0.02).
Next, to examine whether the addition of baPWV and/
or maxIMT to conventional risk factors could improve
the predictability for major CVE, time-dependent ROC
curves were plotted. The addition of maxIMT alone to
FRS significantly increased AUC (from 0.59 [95%CI:
0.51-0.66] to 0.63 [95%CI: 0.55-0.72]; p = 0.01) and the
addition of baPWV to FRS and maxIMT further in-
creased AUC (from 0.63 [95%CI: 0.55-0.72] to 0.72 [95%
CI: 0.65-0.78]; p = 0.02) (Additional file 5: Figure S2).
These results suggested that evaluation of baPWV, in
addition to maxIMT and conventional risk factors, can
substantially improve the ability to identify individuals
















Framingham risk score + maxIMT
Framingham risk score + maxIMT + baPWV
Ref.
Figure 2 Time-dependent ROC curves for predicting cardiovascular events. ROC curves were based on models of the predictability for
cardiovascular events with the use of FRS alone; FRS and maxIMT; or FRS, maxIMT, and baPWV. The AUCs for cardiovascular events were 0.60
[95%CI: 0.54-0.67] (FRS alone), 0.63 [95% CI: 0.60-0.82] (FRS and maxIMT), and 0.72 [95%CI: 0.67-0.78] (FRS, maxIMT, and baPWV). The addition of
maxIMT alone to FRS resulted in a significant increase in AUC (ΔAUC 0.03 [95% CI: 0.01 to 0.11]; p = 0.01). Addition of baPWV to the FRS and
maxIMT resulted in a further significant increase in AUC (0.08 [95% CI: 0.01 to 0.11]; p = 0.02).
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Early detection of asymptomatic severe coronary artery
disease as well as cerebrovascular disease, and subse-
quent rapid intervention, are important to reduce
mortality in the management of diabetes. Although
cardiovascular risk assessment based on the conventional
risk factors is recommended for predicting cardiovascular
risk, validation studies have shown that this approach had
only moderate performance [1-3]. Therefore, a non-invasive
and inexpensive tool to predict the risk of subclinical
or silent atherosclerosis with more than moderate pre-
dictive ability is required for identifying individuals at
high-risk of CVE.
Because baPWV is easy to measure and requires no
special techniques, it could be suitable for screening in
routine care. It has been already shown that baPWV is
closely associated with conventional cardiovascular risk
factors in subjects with and without diabetes [34]. The
present study also demonstrated that there were signifi-
cant associations between conventional cardiovascular
risk factors and baPWV, suggesting that high baPWV
itself reflects inherent cardiovascular risk factors. How-
ever, there was insufficient evidence of its clinical sig-
nificance; although several longitudinal studies have
demonstrated that higher baPWV levels were associ-
ated with increased risk of CVD or mortality among
the general population [11,12,17,18] and high-risk pa-
tients with coronary heart disease or renal diseases
[35-37], it has been unclear whether baPWV level is as-
sociated with increased risk of the development of CVE
in asymptomatic type 2 diabetic patients.
The present study clearly demonstrated that a higher
baPWV level was associated with increased risk of devel-
opment of CVE in asymptomatic type 2 diabetic patients.
Furthermore, a multivariate analysis revealed that baPWV
was still an independent predictor for CVE even after
adjusting for conventional cardiovascular risk factors.These results were consistent with the findings observed
in general populations, and with the idea that diabetic
patients with arterial stiffness are prone to develop CVE.
The present study also confirmed the results of several
previous studies reporting that carotid IMT, a marker of
early atherosclerosis and vascular remodeling, was an
independent predictor of CVE in asymptomatic diabetic
patients [38-40].
Interestingly, type 2 diabetic subjects with both “high
PWV” and “high IMT” had a significantly greater risk of
developing CVE compared to those with either “high
PWV” or “high IMT”, and to those with neither. Fur-
thermore, a multivariate regression model revealed that
both baPWV and maxIMT were significant independent
predictors for CVE, even after adjustment for each other
and the conventional risk factors. These results suggest
that baPWV and maxIMT reflect different aspects of
cardiovascular risk that leads to onset of CVE, and that
measurement of either or both of these two parameters
could substantially improve the risk assessment for fu-
ture CVE compared with the risk assessment based on
conventional cardiovascular risk factors alone.
To test the above hypothesis, the predictability of
baPWV and/or maxIMT for identifying patients at high
risk for CVE was then evaluated over time. Importantly,
measurement of baPWV improved the risk assessment
for future CVE when compared with the Framingham
Risk Score, which is one of the established risk scores
reflecting conventional cardiovascular risk factors. To
the best of our knowledge, this is the first study to dem-
onstrate that adding baPWV to an established risk score
significantly improved the risk assessment for future
CVE in type 2 diabetic patients. The question of whether
measurement of carotid IMT can add prognostic infor-
mation beyond conventional cardiovascular risk markers
remains controversial [40-44]. However, we confirmed
previous findings that the addition of carotid IMT to
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of risk for future CVE, but the improvement of the pre-
dictability was small. Interestingly, the AUC of the
time-dependent ROC curve was further increased after
the addition of baPWV to FRS and maxIMT (from 0.63
to 0.72; p = 0.02). This is the first study to show that
evaluation of the baPWV, in addition to carotid IMT
and conventional risk factors, further improved the
ability to identify individuals with a high risk for CVE.
These findings highlight the clinical usefulness of baPWV
in the risk assessment of CVE among asymptomatic type
2 diabetic patients, suggesting that it can be applied more
broadly in routine care in this group.
Several limitations of our study should be discussed.
First, the sample size and the number of events were
relatively small. Furthermore, there was a gender im-
balance among participants. Second, the primary out-
come was new onset of all cardiovascular events,
including the need for coronary revascularization and
PAD (soft events). However, even if we focus on new
onset of the major CVE, similar results were obtained.
Third, the subjects of this study were Japanese pa-
tients with type 2 diabetes mellitus and were a cohort
with relatively low cardiovascular risk. Although the
incidence of CVE observed was comparable to the
value reported in a previous Japanese study [45], it
was notably lower compared to the incidence observed
in Western diabetic populations [46,47]. Therefore, it
would be premature to generalize our findings to
other racial or ethnic groups or non-diabetic subjects.
It should be also noted that the definitions of hyper-
tension and dyslipidemia adopted in this study were
for Japanese diabetic patients and somewhat different
from those used in Western countries (especially in
the thresholds of systolic blood pressure and serum
LDL cholesterol level). It may reduce comparability of
our study with others concerning the same topic, al-
though we confirmed that the results of the analyses
were almost the same even if we adopted Western def-
initions. Fourth, the development of PAD was consid-
ered one of the components of primary outcome.
However, some asymptomatic PAD cases might have
been overlooked, since ankle-brachial indices were not
measured annually during the observation period in
some cases. Fifth, in some analyses we divided subjects
into two groups according to their baPWV values and
compared the between-group differences. However,
the cut-off value of baPWV used in these analyses was
not based on previous literature but used the median
value of this cohort. Sixth, the ROC curve analysis showed
that the AUC of FRS for predicting risk of CVE in type 2
diabetic patients would be small. However, this was con-
sistent with those of several previous studies, which also
showed a value of around 0.60 [48].The present study focused on the question of whether
measurement of baPWV can provide any useful informa-
tion for identifying patients with a high risk for CVE at a
certain point in their life with diabetes. Our thesis would
have been strengthened if it were shown that measure-
ment of baPWV could improve the risk prediction of
CVE even after adjustment for the therapeutic regimen
during the follow-up period. However, the therapeutic
regimens (e.g. types of agents administered and duration
of administration) used by our study subjects varied
greatly and we were not able to include such a wide
range of parameters in the multivariate regression model,
because the number of observed CVE was insufficient.
Therefore, whether the therapeutic regimens used and/or
longitudinal monitoring of major cardio-metabolic param-
eters during follow-up affects the predictability of baPWV
should be evaluated in further studies.
Notwithstanding these limitations, our study indicates
that measurement of baPWV can provide useful infor-
mation for identifying patients with a high risk of CVE.Conclusions
The present study suggests that baPWV, a non-invasive
and user-friendly method for quantitatively estimating
arterial stiffness, can improve the risk prediction of car-
diovascular events in asymptomatic type 2 diabetic patients.Additional files
Additional file 1: Table S1. Relative risk of cardiovascular events.
Table S2. Relative risk of major cardiovascular events.
Additional file 2: Figure S1A. Kaplan–Meier curves depicting the
cumulative probability of major cardiovascular events in patients with
baPWV values lower than the median (thin line) (<1550 cm/s, n = 520)
and higher than the median (bold line) (≥1550 cm/s, n = 520). The risk
for major cardiovascular events was significantly greater in patients with
higher baPWV values compared to those with lower baPWV values (p= 0.001,
log-rank test).
Additional file 3: Figure S1B. Kaplan–Meier curves depicting the
cumulative probability of major cardiovascular events in patients with
maxIMT values lower than the median (thin line) (<1.0 mm, n = 460) and
higher than the median (bold line) (≥1.0 mm, n = 580). The risk for major
cardiovascular events was significantly greater in patients with higher
maxIMT values compared to those with lower maxIMT values (p = 0.003,
log-rank test).
Additional file 4: Figure S1C. Kaplan–Meier curves depicting the
cumulative probability of major cardiovascular events in patients with
“low baPWV and low maxIMT (baPWV <1550 cm/s and maxIMT <1.0 mm,
n = 279)” (thin gray line), “high baPWV and low maxIMT (baPWV
≥1550 cm/s and maxIMT <1.0 mm, n = 181)” (dotted line), “low baPWV
and high maxIMT (baPWV <1550 cm/s and maxIMT ≥1.0 mm, n = 241)”
(thin black line), and “high baPWV and high maxIMT (baPWV ≥1550 cm/s
and maxIMT ≥1.0 mm)” (bold black line) (n = 580). The cumulative
incidence rate of major cardiovascular events was significantly greater in
the patients with “high baPWV and high maxIMT” compared to the other
3 groups (p < 0.05). Although the patients with “high baPWV and low
maxIMT” and those with “low baPWV and high maxIMT” showed a
tendency towards a higher risk compared to those with “low baPWV and
low maxIMT”, there were no significant differences between the groups.
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http://www.cardiab.com/content/13/1/128Additional file 5: Figure S2. Time-dependent ROC curves for
predicting cardiovascular events. ROC curves were based on models of
the predictability for major cardiovascular events with the use of FRS
alone; FRS and maxIMT; or FRS, maxIMT, and baPWV. The AUCs for major
cardiovascular events were 0.59 [95%CI: 0.51-0.66] (FRS alone), 0.63 [95%
CI: 0.55-0.72] (FRS and maxIMT), and 0.72 [95%CI: 0.65-0.78] (FRS, maxIMT,
and baPWV). The addition of maxIMT to FRS resulted in significant
increase in AUC (ΔAUC = 0.04 [95% CI: 0.00 to 0.09]; p = 0.01). Addition of
baPWV to the FRS and maxIMT resulted in a further significant increase in
AUC (0.09 [95% CI: 0.02 to 0.15]; p = 0.02).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
N.K. and M.S. designed the study, researched data, and wrote the
manuscript. M.T. and T.M. researched the data and contributed to the
interpretation of the results. T.O., Y.Y., and I.S. contributed to the
interpretation of the results and the discussion. All authors reviewed and
approved the report. N.K. is the guarantor of this work and, as such, had full
access to all of the data in the study and takes responsibility for the integrity
of the data and accuracy of the data analysis.
Acknowledgments
Funding Sources: Grants-in-Aid for Scientific Research from the Japanese
Ministry of Education, Science, Sports, Culture and Technology [KAKENHI
25461349] and Takeda Science Foundation.
WILL Medical Communications assisted the authors with proofreading the
manuscript and this assistance was funded by the authors.
Author details
1Department of Metabolic Medicine, Osaka University Graduate School of
Medicine, 2-2, Yamadaoka, Suita 565-0871Osaka, Japan. 2Department of
Metabolism and Atherosclerosis, Osaka University Graduate School of
Medicine, Osaka, Japan. 3Naka Memorial Clinic, Naka City, Japan.
Received: 25 May 2014 Accepted: 20 August 2014
References
1. Stephens JW, Ambler G, Vallance P, Betteridge DJ, Humphries SE, Hurel SJ:
Cardiovascular risk and diabetes. are the methods of risk prediction
satisfactory? Eur J Cardiovasc Prev Rehabil 2004, 11:521–528.
2. Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ,
Griffin SJ: Performance of the UK Prospective Diabetes Study risk engine
and the Framingham risk equations in estimating cardiovascular disease
in the EPIC- Norfolk Cohort. Diabetes Care 2009, 32:708–713.
3. van Dieren S, Peelen LM, Nöthlings U, van der Schouw YT, Rutten GE,
Spijkerman AM, van der ADL, Sluik D, Boeing H, Moons KG, Beulens JW:
External validation of the UK Prospective Diabetes Study (UKPDS) risk
engine in patients with type 2 diabetes. Diabetologia 2011, 54:264–270.
4. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P,
Benetos A: Aortic stiffness is an independent predictor of all-cause and
cardiovascular mortality in hypertensive patients. Hypertension 2001,
37:1236–1241.
5. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D,
Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H: European network
for non-invasive investigation of large arteries. expert consensus document
on arterial stiffness: methodological issues and clinical applications.
Eur Heart J 2006, 27:2588–2605.
6. Laurent S, Boutouyrie P: Recent advances in arterial stiffness and wave
reflection in human hypertension. Hypertension 2007, 49:1202–1206.
7. Laurent S, Katsahian S, Fassot C, Tropeano AI, Laloux B, Boutouyrie P: Aortic
stiffness is an independent predictor of fatal stroke in essential
hypertension. Stroke 2003, 34:1203–1206.
8. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent
S: Aortic stiffness is an independent predictor of primary coronary
events in hypertensive patients: a longitudinal study. Hypertension 2002,
39:10–15.9. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L,
Ibsen H, Jeppesen J: Prognostic value of aortic pulse wave velocity
as index of arterial stiffness in the general population. Circulation
2006, 113:664–670.
10. Suzuki E, Kashiwagi A, Nishio Y, Egawa K, Shimizu S, Maegawa H, Haneda M,
Yasuda H, Morikawa S, Inubushi T, Kikkawa R: Increased arterial wall
stiffness limits flow volume in the lower extremities in type 2 diabetic
patients. Diabetes Care 2001, 24:2107–2114.
11. Turin TC, Kita Y, Rumana N, Takashima N, Kadota A, Matsui K, Sugihara H,
Morita Y, Nakamura Y, Miura K, Ueshima H: Brachial-ankle pulse wave
velocity predicts all-cause mortality in the general population: findings
from the Takashima Study, Japan. Hypertens Res 2010, 33:922–925.
12. Miyano I, Nishinaga M, Takata J, Shimizu Y, Okumiya K, Matsubayashi K,
Ozawa T, Sugiura T, Yasuda N, Doi Y: Association between brachial-ankle
pulse wave velocity and 3-year mortality in community-dwelling older
adults. Hypertens Res 2010, 33:678–682.
13. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori
S, Yamamoto Y: Validity, reproducibility, and clinical significance of
noninvasive brachial-ankle pulse wave velocity measurement. Hypertens
Res 2002, 25:359–364.
14. Tanaka H, Munakata M, Kawano Y, Ohishi M, Shoji T, Sugawara J, Tomiyama
H, Yamashina A, Yasuda H, Sawayama T, Ozawa T: Comparison between
carotid-femoral and brachial-ankle pulse wave velocity as measures of
arterial stiffness. J Hypertens 2009, 27:2022–2027.
15. Kim JH, Rhee MY, Kim YS, Bae JH, Nah DY, Kim YK, Lee MM, Lim C, Kim CJ:
Brachial-ankle pulse wave velocity for the prediction of the presence
and severity of coronary artery disease. Clin Exp Hypertens 2013, Epub
ahead of print.
16. Yiu KH, Zhao CT, Chen Y, Siu CW, Chan YH, Lau KK, Liu S, Lau CP, Tse HF:
Association of subclinical myocardial injury with arterial stiffness in
patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2013, 12:94.
doi: 10.1186/1475-2840-12-94.
17. Nagai K, Shibata S, Akishita M, Sudoh N, Obara T, Toba K, Kozaki K: Efficacy
of combined use of three non-invasive atherosclerosis tests to predict
vascular events in the elderly; carotid intima-media thickness, flow-
mediated dilation of brachial artery and pulse wave velocity.
Atherosclerosis 2013, 231:365–370.
18. Han JY, Choi DH, Choi SW, Kim BB, Ki YJ, Chung JW, Koh YY, Chang KS,
Hong SP: Predictive value of brachial-anklepulse wavw velocity
forcardiovascular events. Am J Med Sci 2013, 346:92–97.
19. Salonen JT, Salonen R: Ultrasonographically assessed carotid morphology and
the risk of coronary heart disease. Atheroscler Thromb 1991, 11:1245–1249.
20. Bots ML, Hoes AW, Koudstaal PJ, Hoffman A, Grobbee DE: Common carotid
intima-media thickness and risk of stroke and myocardial infarction: the
Rotterdam Study. Circulation 1997, 96:1432–1437.
21. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr:
Carotid-artery intima and media thickness as a risk factor for myocardial
infarction and stroke in older adults. Cardiovascular Health Study
Collaborative Research Group. N Engl J Med 1999, 340:14–22.
22. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M: Prediction of clinical
cardiovascular events with carotid intima-media thickness: a systematic
review and meta-analysis. Circulation 2007, 115:459–467.
23. Mukamal KJ, Kizer JR, Djoussé L, Ix JH, Zieman S, Siscovick DS, Sibley CT,
Tracy RP, Arnold AM: Prediction and classification of cardiovascular
disease risk in older adults with diabetes. Diabetologia 2013, 56:275–283.
24. Novo S, Peritore A, Trovato RL, Guarneri FP, Di Lisi D, Muratori I, Novo G:
Preclinical atherosclerosis and metabolic syndrome increase cardio- and
cerebrovascular events rate: a 20-year follow up. Cardiovasc Diabetol
2013, 12(1):155. doi: 10.1186/1475-2840-12-155.
25. Lau KK, Wong YK, Chan YH, Yiu KH, Teo KC, Li LS, Ho SL, Chan KH, Siu CW,
Tse HF: Prognostic implications of surrogate markers of atherosclerosis in
low to intermediate risk patients with type 2 diabetes. Cardiovasc
Diabetol 2012, 11:101. doi: 10.1186/1475-2840-11-101.
26. Japan Diabetes Society, Treatment Guide for Diabetes Editorial Committee:
Diabetes mellitus treatment guideline based on scientific ground
(revised edition 2). Volume 1. Edited by Japan Diabetes Society. Tokyo,
Japan: Nankodo; 2007:257–272.
27. Terminology and Diagnostic Criteria Committee, Japan Society of
Ultrasonics in Medicine: Subcommittee for Preparing Guidelines for
Ultrasound Diagnosis of Carotid Artery. standard method for ultrasound
evaluation of carotid artery lesions. Jpn J Med Ultrasonics 2009, 36:501–518.
Katakami et al. Cardiovascular Diabetology 2014, 13:128 Page 11 of 11
http://www.cardiab.com/content/13/1/12828. The Japanese Circulation Joint Working Group (2000–2001): Guidelines for
management of acute coronary syndrome without persistent ST
segment elevation (JCS 2002). Circ J 2002, 66(Suppl. IV):1123–63.
29. The Japanese Circulation Joint Working Group (2004): Guidelines for
diagnostic evaluation of patients with chronic ischemic heart disease
(JCS 2005). http://www.j-circ.or.jp/guideline/pdf/JCS2005_yokoyama_h.pdf.
30. Special report from the National Institute of Neurological Disorders and
Stroke: Classification of cerebrovascular diseases III. Stroke 1990, 21:637–676.
31. The Japanese Circulation Joint Working Group (2004): Guidelines for
treatment of chronic heart failure (JCS 2005). http://www.j-circ.or.jp/
guideline/pdf/JCS2005_matsuzaki_h.pdf.
32. The Japanese Circulation Joint Working Group (2009): Guidelines for
treatment of chronic heart failure (JCS 2010). http://www.j-circ.or.jp/
guideline/pdf/JCS2010_matsuzaki_h.pdf.
33. Heagerty PJ, Lumley T, Pepe MS: Time-dependent ROC curves for censored
survival data and a diagnostic marker. Biometrics 2000, 56:337–344.
34. Won KB, Chang HJ, Kim HC, Jeon K, Lee H, Shin S, Cho IJ, Park SH, Lee SH,
Jang Y: Differential impact of metabolic syndrome on subclinical
atherosclerosis according to the presence of diabetes. Cardiovasc Diabetol
2013, 12:41. doi: 10.1186/1475-2840-12-41.
35. Nakamura M, Yamashita T, Yajima J, Oikawa Y, Sagara K, Koike A, Kirigaya H,
Nagashima K, Sawada H, Aizawa T, Shinken Database Study Group: Brachial-
ankle pulse wave velocity as a risk stratification index for the short-term
prognosis of type 2 diabetic patients with coronary artery disease.
Hypertens Res 2010, 33:1018–1024.
36. Tomiyama H, Koji Y, Yambe M, Shiina K, Motobe K, Yamada J, Shido N,
Tanaka N, Chikamori T, Yamashina A: Brachial - ankle pulse wave velocity
is a simple and independent predictor of prognosis in patients with
acute coronary syndrome. Circ J 2005, 69:815–822.
37. Kitahara T, Ono K, Tsuchida A, Kawai H, Shinohara M, Ishii Y, Koyanagi H,
Noguchi T, Matsumoto T, Sekihara T, Watanabe Y, Kanai H, Ishida H, Nojima
Y: Impact of brachial-ankle pulse wave velocity and ankle-brachial blood
pressure index on mortality in hemodialysis patients. Am J Kidney Dis 2005,
46:688–696.
38. Yamasaki Y, Kodama M, Nishizawa H, Sakamoto K, Matsuhisa M, Kajimoto Y,
Kosugi K, Shimizu Y, Kawamori R, Hori M: Carotid intima-media thickness
in Japanese type 2 diabetic subjects: predictors of progression and
relationship with incident coronary heart disease. Diabetes Care 2000,
23:1310–1315.
39. Yoshida M, Mita T, Yamamoto R, Shimizu T, Ikeda F, Ohmura C, Kanazawa A,
Hirose T, Kawamori R, Watada H: Combination of the Framingham risk
score and carotid intima-media thickness improves the prediction of
cardiovascular events in patients with type 2 diabetes. Diabetes Care
2011, 35:178–180.
40. Irie Y, Katakami N, Kaneto H, Takahara M, Nishio M, Kasami R, Sakamoto K,
Umayahara Y, Sumitsuji S, Ueda Y, Kosugi K, Shimomura I: The utility of
ultrasonic tissue characterization of carotid plaque in the prediction of
cardiovascular events in diabetic patients. Atherosclerosis 2013, 230:399–405.
41. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, Volcik K,
Boerwinkle E, Ballantyne CM: Carotid intima-media thickness and presence
or absence of plaque improves prediction of coronary heart disease risk:
the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol
2010, 55:1600–1607.
42. Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA, D’Agostino RB Sr:
Carotid-wall intima-media thickness and cardiovascular events. N Engl J
Med 2011, 365:213–221.
43. del Sol AI, Moons KG, Hollander M, Hofman A, Koudstaal PJ, Grobbee DE,
Breteler MM, Witteman JC, Bots ML: Is carotid intima-media thickness
useful in cardiovascular disease risk assessment? the Rotterdam study.
Stroke 2001, 32:1532–1538.
44. den Ruijter HM, Peters SAE, Groenewegen KA, Anderson TJ, Britton AR,
Dekker JM, Engström G, Eijkemans MJ, Evans GW, de Graaf J, Grobbee DE,
Hedblad B, Hofman A, Holewijn S, Ikeda A, Kavousi M, Kitagawa K, Kitamura
A, Koffijberg H, Ikram MA, Lonn EM, Lorenz MW, Mathiesen EM, Nijpels G,
Okazaki S, O’Leary DH, Polak JF, Price JF, Robertson C, Rembold CM, et al:
Common carotid intima-media thickness does not add to Framingham
risk score in individuals with diabetes mellitus: the USE-IMT initiative.
Diabetologia 2013, 56:1494–1502.
45. Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi
S, Katayama S, Ohashi Y, Akanuma Y, Yamada N, for the Japan Diabetes
Complications Study Group: Serum level of triglycerides is a potent riskfactor comparable to LDL cholesterol for coronary heart disease in
Japanese patients with type 2 diabetes: subanalysis of the Japan
Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 2011,
96:3448–3456.
46. Prediction of Coronary Heart Disease Risk in a General: Pre-diabetic, and diabetic
population during 10 years of follow-up: accuracy of the Framingham, SCORE,
and UKPDS risk functions. Diabetes Care 2009, 32:2094–2098.
47. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM,
Lawrenson RA, De Vries CS: Risk of stroke in people with type 2 diabetes
in the UK: a study using the general practice research database.
Diabetologia 2006, 49:2859–2865.
48. Kengne AP, Patel A, Colagiuri S, Heller S, Hamet P, Marre M, Pan CY,
Zoungas S, Grobbee DE, Neal B, Chalmers J, Woodward M, ADVANCE
Collaborative Group: The Framingham and UK Prospective Diabetes
Study (UKPDS) risk equations do not reliably estimate the probability
of cardiovascular events in a large ethnically diverse sample of patients
with diabetes: the Action in Diabetes and Vascular Disease: Preterax and
Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia 2010,
53:821–831.
doi:10.1186/s12933-014-0128-5
Cite this article as: Katakami et al.: Clinical utility of brachial-ankle pulse
wave velocity in the prediction of cardiovascular events in diabetic patients.
Cardiovascular Diabetology 2014 13:128.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
